AbCellera Biologics Total Assets 2019-2024 | ABCL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AbCellera Biologics total assets from 2019 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AbCellera Biologics total assets from 2019 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.9B
Regeneron Pharmaceuticals (REGN)	$125.5B
Vertex Pharmaceuticals (VRTX)	$122.4B
Gilead Sciences (GILD)	$104.4B
Bristol Myers Squibb (BMY)	$100.8B
CSL (CSLLY)	$96.8B
GSK (GSK)	$87.9B
Alnylam Pharmaceuticals (ALNY)	$35.1B
Argenex SE (ARGX)	$31.6B
Biogen (BIIB)	$28.8B
BioNTech SE (BNTX)	$27.5B
Moderna (MRNA)	$26.9B
Illumina (ILMN)	$20.9B
BeiGene (BGNE)	$19.2B
Genmab (GMAB)	$17.3B
BioMarin Pharmaceutical (BMRN)	$13.5B
Vaxcyte (PCVX)	$13B
Exact Sciences (EXAS)	$12.8B
Incyte (INCY)	$12.6B
Insmed (INSM)	$12.5B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.4B
Bio-Rad Laboratories (BIO.B)	$9.1B
Legend Biotech (LEGN)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.7B
Repligen (RGEN)	$8B
Intra-Cellular Therapies (ITCI)	$7.9B
Halozyme Therapeutics (HALO)	$7.9B